BUZZ — Australia's Orthocell rises as flagship product records first Thailand sales

* Shares of Orthocell rise as much as nearly 8% to A$0.745, marking their highest level since September 1 * Shares on track for their best day since August 11, if gains hold * The regenerative medicine achieves first commercial sales of flagship product Remplir in Thailand * About 442,385 shares change hands, 1.9x the 30-day average of 238,579 * Stock down 33.4%, YTD, including moves in current session (Reporting by Jasmeen Ara Shaikh in Bengaluru) ((Jasmeenaraislam.Shaikh@thomsonreuters.com;)